DRUG
LY3437943
Administered SC.
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Status
Completed
Phase
Phase 1
Enrollment
43
Locations
5
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Jun 23, 2023
Study start
Jul 13, 2023
Primary completion
Mar 2, 2025
Study completion
Mar 2, 2025
Results posted
Not reported
Registry updated
Apr 18, 2025
Outcomes
What the study measures.
Primary outcomes
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943
Time frame · Predose up to 30 days postdose
PK: AUC0-∞ of LY3437943
PK: Maximum observed concentration (Cmax) of LY3437943
Time frame · Predose up to 30 days postdose
PK: Cmax of LY3437943
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: All Participants: * Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive * Healthy or various degrees of hepatic impairment depending on the study group Exclusion Criteria: Participants with hepatic impairment: * Have or are anticipating an organ transplant within the next 6 months * Requires needle evacuation of ascites fluid more than 2 times per month * Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure
Study locations
5 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Arizona Clinical Trials - Chandler
Chandler, Arizona, United States
Accel Research Sites- Clinical Research Unit
DeLand, Florida, United States
Advanced Pharma Clinical Research
Miami, Florida, United States
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States
Pinnacle Clinical Research
San Antonio, Texas, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.